MEDROXYPROGESTERONE PLUS TAMOXIFEN FOR ADVANCED RENAL-CELL CARCINOMA

被引：0
|
作者：
FUKS, JZ [1 ]
VANECHO, DA [1 ]
AISNER, J [1 ]
OSTROW, S [1 ]
WIERNIK, PH [1 ]
机构：
[1] UNIV MARYLAND HOSP,BALTIMORE CANC RES CTR,BALTIMORE,MD 21201
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1982年 / 23卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [1] MEDROXYPROGESTERONE IN METASTATIC RENAL-CELL CARCINOMA
    RAO, MK
    SOLOWAY, MS
    [J]. SOUTHERN MEDICAL JOURNAL, 1980, 73 (02) : 247 - 248
  • [2] PHASE-II STUDY OF MEDROXYPROGESTERONE ACETATE WITH TAMOXIFEN IN ADVANCED RENAL-CELL CANCER
    FUKS, JZ
    AISNER, J
    VANECHO, DA
    WIERNIK, PH
    [J]. CANCER TREATMENT REPORTS, 1982, 66 (09): : 1773 - 1774
  • [3] LACK OF THERAPEUTIC EFFICACY OF TAMOXIFEN IN ADVANCED RENAL-CELL CARCINOMA
    SCHOMBURG, A
    KIRCHNER, H
    FENNER, M
    MENZEL, T
    POLIWODA, H
    ATZPODIEN, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) : 737 - 740
  • [4] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [5] TAMOXIFEN IN METASTATIC RENAL-CELL CARCINOMA
    MULDER, JH
    ALEXIEVAFIGUSCH, I
    [J]. CANCER TREATMENT REPORTS, 1979, 63 (07): : 1222 - 1222
  • [6] COMBINED CHEMOENDOCRINE TREATMENT WITH TEGAFUR AND TAMOXIFEN FOR ADVANCED RENAL-CELL CARCINOMA
    WADA, T
    NISHIYAMA, K
    MAEDA, M
    HARA, S
    TANAKA, N
    YASUTOMI, M
    KURITA, T
    [J]. ANTICANCER RESEARCH, 1995, 15 (04) : 1581 - 1584
  • [7] TAMOXIFEN TREATMENT FOR ADVANCED RENAL-CELL CANCER
    FERRAZZI, E
    SALVAGNO, L
    FORNASIERO, A
    CARTEI, G
    FIORENTINO, M
    [J]. TUMORI, 1980, 66 (05) : 601 - 605
  • [8] PHASE-II STUDY OF TAMOXIFEN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    GLICK, JH
    WEIN, A
    TORRI, S
    ALAVI, J
    HARRIS, D
    BRODOVSKY, H
    [J]. CANCER TREATMENT REPORTS, 1980, 64 (2-3): : 343 - 344
  • [9] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Motzer, Robert J.
    Penkov, Konstantin
    Haanen, John
    Rini, Brian
    Albiges, Laurence
    Campbell, Matthew T.
    Venugopal, Balaji
    Kollmannsberger, Christian
    Negrier, Sylvie
    Uemura, Motohide
    Lee, Jae L.
    Vasiliev, Aleksandr
    Miller, Wilson H., Jr.
    Gurney, Howard
    Schmidinger, Manuela
    Larkin, James
    Atkins, Michael B.
    Bedke, Jens
    Alekseev, Boris
    Wang, Jing
    Mariani, Mariangela
    Robbins, Paul B.
    Chudnovsky, Aleksander
    Fowst, Camilla
    Hariharan, Subramanian
    Huang, Bo
    di Pietro, Alessandra
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
  • [10] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
12345